[Special Stock] Newgislab Pharma to Start Clinical Trial of Anti-inflammatory Cancer Drug KAT in August... Initial Data to Be Released Within the Year Up

[Asia Economy Reporter Jang Hyowon] Newgelab Pharma is showing strong performance. This is interpreted as being driven by expectations that clinical trials for the metabolic anticancer drug ‘KAT’ will begin in August and that initial data will be announced within the year.

As of 2:21 PM on the 28th, Newgelab Pharma is trading at 11,000 KRW, up 5.77% from the previous day.

Newgelab Pharma is preparing clinical trials for ‘KAT,’ a new mechanism anticancer drug that blocks cancer metabolism. In August last year, it received an Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) for liver cancer, and in April, it also received IND approval from the Korean Ministry of Food and Drug Safety. Clinical trials targeting liver cancer patients will be conducted at three hospitals in Korea and two in the U.S.

Oh Byungyong, a researcher at Hanyang Securities, said, “Newgelab Pharma is currently awaiting IRB (Institutional Review Board) approval from Seoul National University Hospital, the main clinical site, and patient recruitment is expected to begin immediately once the IRB approval is granted in August.” He added, “The company is confident in the excellent efficacy of KAT treatment cases based on clinical trial data and plans to disclose data from early-stage patients to the market.”

He further stated, “Newgelab Pharma’s new drug potential is not inferior compared to other anticancer drug development companies.”

This content was produced with the assistance of AI translation services.